Seres Therapeutics(US:MCRB)2025-08-06 12:30Seres Therapeutics Overview - Seres' VOWST, the first-ever oral live microbiome therapeutic, received FDA approval in April 2023 for preventing C difficile infection recurrence, demonstrating approximately 88% sustained clinical response rate[6,9] - The sale of the VOWST asset, completed in September 2024, provided Seres with capital to support pipeline advancement and streamline the organization[9,10] - As of June 30, 2025, Seres had approximately $45.4 million in cash and cash equivalents, projecting a cash runway into Q1 2026[92] SER-155 Clinical Development - SER-155 Phase 1b data in allo-HSCT showed a 77% relative risk reduction in bacterial bloodstream infections (BSIs) compared to placebo[6,45,92] - SER-155 Phase 1b data also showed significantly lower mean cumulative exposure to systemic antibacterials/antimycotics compared to placebo (9.2 days vs 21.1 days)[45,50] - SER-155 Phase 1b data also showed a lower incidence rate of febrile neutropenia in SER-155-treated subjects vs placebo[46] - A Phase 2 study protocol for SER-155 in allo-HSCT was submitted to the FDA in May 2025, with study commencement dependent on funding and aiming to enroll 248 patients[6,31,78] Pipeline and Future Opportunities - Seres is developing SER-147 to prevent infections in chronic liver disease patients, with preclinical data showing a 1-3 log reduction of E coli in in vitro models[6,80] - Seres is also developing SER-603 to target inflammatory drivers of Inflammatory Bowel Disease (IBD)[83] - Seres is engaging with multiple parties regarding various deal structures to secure capital for the clinical advancement of SER-155 and other live biotherapeutic product candidates[6,78,92]